prospective partnerships for industry and academia emily gale medical research council 21 november...
TRANSCRIPT
Prospective partnerships for industry and academia
• Encourage and support high-quality research with the aim of improving human health.
• Produce skilled researchers.
• Advance and disseminate knowledge and technology to improve the quality of life and economic competitiveness in the UK and worldwide.
• Promote dialogue with the public about medical research.
MRC mission
• Encourage and support high-quality researchwith the aim of improving human health.
• Produce skilled researchers.
• Advance and disseminate knowledge andtechnology to improve the quality of life andeconomic competitiveness in the UK and worldwide.
• Promote dialogue with the public aboutmedical research.
• Work with industry to drive economic development
Post-Comprehensive Spending Review
• Rickets caused by lack of vitamin D (1916) • Discovery and development of penicillin (1940s)• Pioneered randomised controlled trial design (1940s)• Discovery of link between smoking and cancer (1950s)• Clinical trials for radiotherapy for cancer (1960s)• Clinical trials of chemotherapy for leukaemia (1970s)• Invention of DNA fingerprinting (1980s)• Gene for Huntington’s disease discovered (1990s)• Humanised therapeutic antibodies in widespread use (2000s)
MRC discoveries and developments
MRC investment in research, 2012/13
MRC research expenditure - £766.9 million in 12/13
• £343.1m for more than 400 programmes in MRC research units and institutes.
• £334.6m on 1,400 grants to researchers in universities, medical schools and research institutes.
• £71.3m on training and career development.
• £54.2m on individual grants with industry partners
• £29.5m on industry/academic consortia
MRC resources available to researchers from industry and academia
• MRC research underpins R&D– Patient Research Cohorts Initiative– UK Biobank– UK Brain Bank Network– WT/MRC Stem Cell Centre– Developing animal models– FARR Institute– Clinical trials and methodology resources
• MRC engagement directly with industry
Discovery and exploratory research Application and delivery research
MRC lead NIHR lead
Pharmacogenomics
Animal/human models
Regenerative medicine
Genetics/genomics
Structural biology
Imaging
Systems medicine
Global health
Ageing: life course
Stem cells
Infections
Population science
Experimental medicine
Methodology
Global health
Stratified medicine
Public health
E-health
HTA Trials
EME Trials(Late stage III)
Programmes in
Applied research
Research for Patient Benefit
Invention for Innovation
Service Delivery and Organisation
CSO (Scotland)
WORD (Wales)
HSCNI (Northern Ireland)
Current focuses of MRC activity
Where industry and MRC academics meet
• 92 new products and interventions launched onto the market.
• Creation or growth of 104 companies, 56 formed since 2006.
• 578 patents granted or published since 2006, with around 30% licensed.
• More than 100 new industry collaborations are reported every year outside of the MRC-mediated collaborations.
• Cross-sector MRC funded partnerships
Types of products and interventionsgenerated by MRC-supported scientists
MICA – a gateway to funding
• Encouraging and supporting collaborative research projects between academic and industry researchers.
• Key feature: Flexibility– Level and nature of industry contribution can vary– Companies of any size can participate– Applies to all MRC funding and fellowship schemes
• Agreement between partners forms part of application.
• >80 awards so far, including collaboration involving:– 38 different HEI– 50 different industry partners
MICA: “More thanjust money”
• MenBioVax: meningitis vaccine developed by ImmBio with TSB funding following a collaborative programme with Bristol Medical School
• MRC DPFS funding to take MenBioVax through preclinical studies
“There aren’t many other sources of funding for this type of project in the UK. It brings more than just money, of course. It’s important for potential investors to be able to see that bodies like the MRC have confidence in our technology and products.”
Graham Clarke, ImmBio CEO
MICA: “A very positive experience”
• Evaluation of a potential biomarker for idiopathic pulmonary fibrosis.
• Collaboration between scientists at University of Nottingham, GlaxoSmithKline and Queen Mary, University of London
• “We all believe in the target but each of us has only one piece of the jigsaw.”
“MICA is a tremendous initiative that will accelerate the development of new drugs to meet clinical needs.”
Dr Andy Blanchard
Director of External Discovery, GSK
MICA numbers on the rise
MRC working with industry
•MRC engages directly with industry– DSTT– MRC/ABPI Inflammation and Immunology Initiative– Stratified Medicines Innovation Platform
•MRC promotes partnerships and translational science– MRC/AZ Mechanisms of disease– Confidence in Concept– DPFS/DCS– BMC – Biomedical Catalyst– Bioinformatics call– Experimental Medicine Challenge Grants
•PPP in Europe
Inflammation and Immunology Initiative
A new way of funding from the MRC
• Collaboration with ABPI: Disease-focused workshops
• COPD• Rheumatoid arthritis
Brought together experts from academia and industry Identified research priorities Ear-marked funds for research consortiums to address
barriers and exploit opportunities MRC invested £9.5m over four years
Stratified Medicine Consortia
Disease-focused cross-sector consortia• Pitzalis• Gaucher’s disease• Hepatitis C• Psoriasis• Schizophrenia• Primary Biliary Cirrosis
MRC invested £50m over four yearsExploiting existing expertise and clinical research infrastructure
Aim to provide a dynamic platform for disease focused research
RA Partners
MRC working with industry
•MRC engages directly with industry– DSTT– MRC/ABPI Inflammation and Immunology Initiative– Stratified Medicines Innovation Platform
•MRC promotes partnerships and translational science– MRC/AZ Mechanisms of disease– Confidence in Concept– DPFS/DCS– BMC – Biomedical Catalyst– Experimental Medicine Challenge Grants
•PPP in Europe
Products and interventions by pipeline stage
Initial development
Refinement,Non-clinical
Refinement,Clinical
Early clinical assessment
Late clinical evaluation
Market authorisation
Small-scale adoption
Wide-scale adoption
“Investable opportunities”
• Over 600 projects developing new products or interventions - at all stages of development have been reported
• 110 have reached the market since 2006
• For the first time we can track all of these, noting which are active, closed, seeking support, and which are progressing
• 75% of projects are prior to the “valley of death”, 25% after
• Around 80 would benefit from further investment – so could be “investable opportunities”
• The first year in which we published this data (2011) the three hundred development projects were used by the science minister as an example of the untapped potential that the biomedical catalyst could unlock
“Valley of death”
To provide European citizens with timely access to new and effective diagnostics and treatments that improve their health and wellbeing
Helping safeguard the future
international competitiveness of the European biopharmaceutical industry and secure growth and jobs.
General Objectives of IMI 2
The European Union and the
pharmaceutical industry
have joined forces to make
drug R&D processes in Europe more
innovative and efficient,
enhance Europe’s competitiveness
& address key societal challenges
by forming
the biggest PPP in Life Science
•22
Innovative Medicines Initiative:Joining forces in the healthcare sector
COMBACTE CLIN-Network
280 members and Candidate members
22 million euros awarded to UK SMEs
1 in 4 UK SME applicants are successful in IMI
Thinking about cross-sector collaboration
Bioinformatics
•Computer science
•Data management
Diagnostics
•Engineering
•Microscopy/scanning
•Clinical biology
• What is it? Turning discoveries into clinical benefits, while maintaining the basic research that drives it.
• The MRC’s translational strategy:– builds on the MRC’s existing role in pushing forward basic
knowledge to improve people’s health and wealth– strengthens the support and oversight of the translational
processes
Basic medical research
Prototype discovery and design
Pre-clinical development
Early clinical trials
Late clinical trials
Translation
Translation of basic research takes time
1973 Mouse antibodies isolated by César Milstein and George Köhler (MRC Laboratory of Molecular Biology)
1986 Michael Neuberger and Sir Greg Winter ‘humanise’ mouse antibodies
Sir Greg develops and patents technology for producing antibodies in vitro
2003 MRC-developed Humira® licensed to treat UK arthritis patients
2008 21 monoclonal antibody drugs on market for treating breast cancer, leukaemia, asthma, arthritis, psoriasis and transplant rejection
2011 Antibodies make up 1/3 of new drugs for cancer, arthritis and asthma; global antibody market estimated to be worth $40bn
MRC spend by research activity, 2010/11
MRC spend by health category, 2010/11